Results 61 to 70 of about 466,117 (305)

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

npj Breast Cancer
This multicenter observational study investigated the prognosis of patients who participated in the Phase III POTENT trial, which examined combining S-1 with standard endocrine therapy in patients with estrogen receptor-positive, HER2-negative early ...
Masahiro Takada, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Hiroji Iwata, Tomoharu Sugie, Kenjiro Aogi, Shin Takayama, Nobuaki Sato, Yuichiro Kai, Masahiro Kitada, Rikiya Nakamura, Kenichi Watanabe, Yutaka Matsuyama, Masakazu Toi   +19 more
doaj   +1 more source

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Cell Reports, 2019
Summary: Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs.
Kimberly J. Cocce, Jeff S. Jasper, Taylor K. Desautels, Logan Everett, Suzanne Wardell, Thomas Westerling, Robert Baldi, Tricia M. Wright, Kendall Tavares, Alex Yllanes, Yeeun Bae, Jeremy T. Blitzer, Craig Logsdon, Daniel P. Rakiec, David A. Ruddy, Tiancong Jiang, Gloria Broadwater, Terry Hyslop, Allison Hall, Muriel Laine, Linda Phung, Geoffrey L. Greene, Lesley-Ann Martin, Sunil Pancholi, Mitch Dowsett, Simone Detre, Jeffrey R. Marks, Gregory E. Crawford, Myles Brown, John D. Norris, Ching-yi Chang, Donald P. McDonnell   +31 more
doaj   +1 more source

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial [PDF]

, 2012
Licensed under a Creative Commons Attribution Non-Commercial Share Alike ...
A Howell, B Bonanni, H Brauch, HS Lim, I Sestak, I Sestak, J Cuzick, J Cuzick, J Cuzick, J Cuzick, J F Forbes, J Tyrer, JE Mortimer, JM Rae, K Kiyotani, L Azoulay, M Fontecha, M Nikoloff, MJ Higgins, MM Regan, MP Goetz, MP Goetz, NL Henry, P Wegman, R Kealy, S Borges, SA Nowell, U Veronesi, U Veronesi, W Schroth, Y Xu, Z Desta   +31 more
core   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

The potential of chimeric antigen receptor -T cell therapy for endocrine cancer

World Journal of Surgical Oncology
Endocrine cancer, a relatively rare and heterogeneous tumor with diverse clinical features. The facile synthesis of hormones further complicates endocrine cancer treatment.
Ruonan Yu, Xiaoyu Ji, Ping Zhang, Hao Zhang, Huiling Qu, Wenwu Dong   +5 more
doaj   +1 more source

Endocrine Therapy – What Else? [PDF]

Breast Care, 2008
Endocrine therapy was the first targeted therapy in breast cancer. In 1896, George Thomas Beatson reported the successful treatment of three young women who had locally advanced breast cancer by removing the ovaries [1]. Beatson understood that ‘there is some ovarian influence which works the change'.
openaire   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The serum uric acid-to-high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality: a cross-sectional study

Frontiers in Endocrinology
ObjectiveThe exact relationship between the serum uric acid-to-HDL cholesterol ratio (UHR) and mortality rates remains enigmatic among American adults. This study aims to clarify the association between UHR and both all-cause and cardiovascular disease ...
Zhanbin Li, Zhanbin Li, Zhanbin Li, Zhanbin Li, Zhanbin Li, Zhanbin Li, Qiaoran Liu, Zhenyu Yao, Zhenyu Yao, Zhenyu Yao, Zhenyu Yao, Zhenyu Yao, Zhenyu Yao   +12 more
doaj   +1 more source

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source